Tasly Pharmaceutical Plans to Buy Wealth Management Products of Up to 3 Billion Yuan

MT Newswires Live09-18

Tasly Pharmaceutical Group (SHA:600535) proposed to purchase bank wealth management products of up to 3 billion yuan to use its idle funds, according to a Shanghai bourse filing on Thursday.

The term of the product investment will not exceed six months.

The proposal is subject to shareholders' approval, the Chinese pharmaceutical company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment